Research and Markets: Introducing The Payer Perspective on the Most Pertinent Issues in Rheumatology, Including Reactions

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/37cb6e/2010_state_of_rheu) has announced the addition of the "2010 State of Rheumatology Special Report, 'The Payer Presepective on the Most Pertinent Issues in Rheumatology, Including Reactions to Key Clinical and Economic Data Presentations at the 2010 ACR Scientific Meeting'" report to their offering.

Rheumatology is a dynamic and evolving therapeutic area high on the radar of Commercial and Government Payers. With the proliferation of biologics and products that rely on personalized medicine, the rheumatology market landscape continues to evolve rapidly. Payers are increasing their focus on management of therapies in high cost categories like rheumatoid arthritis, osteoporosis, osteoarthritis, and psoriatic arthritis by implementing controls to ensure appropriate utilization and minimization of cost. This focus on cost-minimization presents significant challenges for manufacturers with both current and pipeline products.

The Reimbursement IQ (RIQ): 2010 State of Rheumatology Special Report provides comprehensive analysis of key targeted therapeutic areas, including rheumatoid arthritis, osteoporosis, osteoarthritis, psoriatic arthritis, and other critical disease states. This insightful report will uncover Payer decision-makers perspectives across a wide range of topics, including:

Market Landscape Assessment

Treatment algorithm evaluation including assessment of perceived points of differentiation and value story of existing treatments

Management of Current Treatment

Options Assessment of formulary status for current treatment options

Perception of Unmet Needs

Clinical endpoints as well as economic factors

Future Market Trends and Expectations

Expectations for changes in market landscape including scenario and price sensitivity analysis

Evaluation of New Market Entrants

Clinical and economic value assessment based on the latest clinical trial data presented at ACR

This insightful report will uncover Payer decision-makers' perspectives across a wide range of topics:

  • Market Landscape Assessment
  • Management of Current Treatment Options
  • Perception of Unmet Needs
  • Future Market Trends and Expectations
  • Evaluation of New Market Entrants

Methodology

Reimbursement Intelligence will conduct the Reimbursement IQ: 2010 State of Rheumatology Special Report survey following the close of the ACR meeting on November 6-11, 2010 in Atlanta, Georgia. The survey will be fielded to 50 Medical and Pharmacy Directors, representing the largest national and regional Commercial/Medicare plans and Medicaid states.

  • Purchasers have the opportunity to add confidential and/or proprietary questions about any area or product relevant to rheumatology
  • Reimbursement Intelligence will provide an in-person presentation of the results for purchasing companies

Why Purchase the Reimbursement IQ: 2010 State of Rheumatology Special Report?

  • Understand the current and future market landscape of the targeted therapy areas from a reimbursement and market access perspective
  • Gauge level of perceived clinical and economic unmet needs
  • Gain insight into the payers approach to management of current and pipeline products

Key Topics Covered:

  • Rheumatoid Arthritis Treatment Landscape
  • RA Management of Current Therapies:
  • Simponi
  • Actemra
  • Enbrel
  • Orencia
  • Rituxan
  • Cimzia
  • Payer Evaluation of Future Pipeline Therapy:
  • JAK Inhibitors
  • SYK Inhibitors
  • Interleukins
  • Rheumatoid Arthritis Unmet Needs
  • Psoriatic Arthritis Current and Future Management

Products Mentioned:

  • Enbrel (etanercept)
  • Humira (adalimumab)
  • Remicade (infliximab)
  • Simponi (golimumab)
  • Cimzia (certolizumab)
  • Orencia (abatacept)
  • Rituxan (rituximab)
  • Actemra (tocilizumab)
  • Methotrexate
  • Stelara (ustekinumab)
  • briakinumab
  • JAK Inhibitors
  • SYK Inhibitors
  • Interleukins

For more information visit http://www.researchandmarkets.com/research/37cb6e/2010_state_of_rheu.



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United States  North America  Georgia

INDUSTRY KEYWORDS:   Health  Hospitals  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.